Jim Simons
MGRX icon

Jim Simons’s Mangoceuticals MGRX Stock Holding History

Jim Simons’s Portfolio MGRX Stock Details MGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-31,000
Closed -$47.1K – 3749
2025
Q2 		$47.1K Buy
+31,000
New +$58.2K ﹤0.01% 3401
2024
Q1 		– Sell
-2,031
Closed -$8K – 3931
2023
Q4 		$8K Buy
+2,031
New +$18K ﹤0.01% 3654

Other funds holding MGRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACA
Ackerman Capital Advisors Dallas, Texas $497M AUM 16.31% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SS
Sunbelt Securities Houston, Texas $1.58B AUM 28.96% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jim Simons's MGRX Position: Q3 2025 in Review

Jim Simons sold out of Mangoceuticals (MGRX) in Q3 2025, closing a stake of 31,000 shares — an estimated $47.1K sold.

Jim Simons first reported a position in MGRX in Q4 2023 and held it in 2 quarters. The position peaked at $47.1K in Q2 2025. 11 funds tracked by Wall St. Rank hold MGRX as of Q3 2025.

  • Jim Simons reported no remaining Mangoceuticals position as of Q3 2025 after selling out during the quarter.
  • Jim Simons sold 31,000 Mangoceuticals shares in Q3 2025, an estimated $47.1K.
  • Jim Simons first reported a position in Mangoceuticals in Q4 2023 and held it in 2 quarters.
  • Jim Simons's Mangoceuticals position peaked at $47.1K in Q2 2025.
  • 11 funds tracked by Wall St. Rank held Mangoceuticals as of Q3 2025.

Based on Renaissance Technologies's 13F filing for Q3 2025, filed 13 Nov 2025.